NBIX
VENTE TOTALE: 1 250 titres (~227 507,50 $ US)
- Insiders
- Norwalk Leslie V
- Total bought
- —
- Total sold
- $227,508
- Last activity
- 2026-07-28
- Last synced
-
2026-08-03 10:19:38
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bullish signal Scored 2026-08-03
NBIX delivers a compelling combination of strong financial health (net cash position, margin expansion, robust FCF) and a high-conviction earnings catalyst, with 39% YoY revenue growth to $959M, a significant EPS beat…
The first sentence of the analysis written for NBIX on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 98.2% | 98.6% | 97.9% | 98.4% | 98.7% | |
| Ebit Margin | 22.3% | 26.0% | 20.9% | 14.8% | 11.2% | |
| Ebitda Margin | 23.3% | 27.2% | 22.0% | 15.9% | 12.2% | |
| Operating Profit Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | |
| Pretax Profit Margin | 24.7% | 20.6% | 17.6% | 14.4% | 8.9% | |
| Continuous Operations Profit Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | |
| Net Profit Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | |
| Bottom Line Profit Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | |
| Current Ratio | 3.393 | 3.397 | 2.454 | 2.703 | 3.958 | |
| Quick Ratio | 3.301 | 3.284 | 2.396 | 2.638 | 3.834 | |
| Solvency Ratio | 0.369 | 0.326 | 0.266 | 0.257 | 0.144 | |
| Cash Ratio | 0.959 | 0.459 | 0.383 | 0.489 | 1.386 | |
| Price To Earnings Ratio | 29.486 | 40.147 | 51.469 | 74.186 | 89.653 | |
| Price To Earnings Growth Ratio | 0.711 | 1.224 | 0.872 | 1.068 | -1.146 | |
| Forward Price To Earnings Growth Ratio | 0.711 | 1.224 | 0.872 | 1.068 | -1.146 | |
| Price To Earnings Diluted Ratio | 30.370 | 41.489 | 53.344 | 76.564 | 92.576 | |
| Price To Earnings Diluted Growth Ratio | 0.724 | 1.250 | 0.914 | 1.101 | -1.189 | |
| Price To Book Ratio | 4.338 | 5.292 | 5.767 | 6.700 | 5.864 | |
| Price To Sales Ratio | 4.933 | 5.819 | 6.822 | 7.686 | 7.108 | |
| Price To Free Cash Flow Ratio | 18.849 | 24.595 | 35.600 | 35.436 | 34.565 | |
| Price To Operating Cash Flow Ratio | 18.030 | 23.017 | 33.016 | 33.713 | 31.412 | |
| Debt To Assets Ratio | 0.090 | 0.122 | 0.132 | 0.111 | 0.212 | |
| Debt To Equity Ratio | 0.128 | 0.176 | 0.192 | 0.154 | 0.321 | |
| Debt To Capital Ratio | 0.113 | 0.149 | 0.161 | 0.133 | 0.243 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.196 | |
| Financial Leverage Ratio | 1.424 | 1.436 | 1.457 | 1.387 | 1.508 | |
| Working Capital Turnover Ratio | 1.909 | 2.172 | 2.020 | 1.812 | 1.456 | |
| Operating Cash Flow Ratio | 1.053 | 1.173 | 0.595 | 0.631 | 1.044 | |
| Operating Cash Flow Sales Ratio | 0.274 | 0.253 | 0.207 | 0.228 | 0.226 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.957 | 0.936 | 0.927 | 0.951 | 0.909 | |
| Debt Service Coverage Ratio | 0.000 | 3.910 | 1.910 | 1.004 | 4.895 | |
| Interest Coverage Ratio | 0.000 | 4.506 | 54.543 | 35.070 | 3.973 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 2.292 | 2.004 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 1.885 | 1.308 | 0.910 | 1.291 | 0.582 | |
| Capital Expenditure Coverage Ratio | 23.021 | 15.586 | 13.777 | 20.570 | 10.962 | |
| Dividend Paid And Capex Coverage Ratio | 23.021 | 15.586 | 13.777 | 20.570 | 10.962 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 20.724 | 21.771 | 31.363 | 48.362 | 59.064 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 98.2% | ▼-0.4% | ▼-0.2% |
| Ebit Margin | 22.2% | ▼-3.8% | ▲3.2% |
| Ebitda Margin | 23.3% | ▼-3.9% | ▲3.2% |
| Operating Profit Margin | 21.6% | ▼-2.6% | ▲4.7% |
| Pretax Profit Margin | 24.7% | ▲4.0% | ▲7.4% |
| Continuous Operations Profit Margin | 16.7% | ▲2.2% | ▲4.2% |
| Net Profit Margin | 16.7% | ▲2.2% | ▲4.2% |
| Bottom Line Profit Margin | 16.7% | ▲2.2% | ▲4.2% |
| Current Ratio | 3.393 | ▼-0.004 | ▲0.212 |
| Quick Ratio | 3.301 | ▲0.017 | ▲0.210 |
| Solvency Ratio | 0.369 | ▲0.043 | ▲0.097 |
| Cash Ratio | 0.959 | ▲0.500 | ▲0.224 |
| Price To Earnings Ratio | 29.486 | ▼-10.661 | ▼-27.502 |
| Price To Earnings Growth Ratio | 0.711 | ▼-0.512 | ▲0.165 |
| Forward Price To Earnings Growth Ratio | 0.711 | ▼-0.512 | ▲0.165 |
| Price To Earnings Diluted Ratio | 30.370 | ▼-11.119 | ▼-28.498 |
| Price To Earnings Diluted Growth Ratio | 0.724 | ▼-0.526 | ▲0.164 |
| Price To Book Ratio | 4.338 | ▼-0.954 | ▼-1.254 |
| Price To Sales Ratio | 4.933 | ▼-0.885 | ▼-1.540 |
| Price To Free Cash Flow Ratio | 18.849 | ▼-5.747 | ▼-10.960 |
| Price To Operating Cash Flow Ratio | 18.030 | ▼-4.987 | ▼-9.808 |
| Debt To Assets Ratio | 0.090 | ▼-0.033 | ▼-0.044 |
| Debt To Equity Ratio | 0.128 | ▼-0.048 | ▼-0.066 |
| Debt To Capital Ratio | 0.113 | ▼-0.036 | ▼-0.047 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.039 |
| Financial Leverage Ratio | 1.424 | ▼-0.012 | ▼-0.019 |
| Working Capital Turnover Ratio | 1.909 | ▼-0.262 | ▲0.035 |
| Operating Cash Flow Ratio | 1.053 | ▼-0.120 | ▲0.154 |
| Operating Cash Flow Sales Ratio | 0.274 | ▲0.021 | ▲0.036 |
| Free Cash Flow Operating Cash Flow Ratio | 0.957 | ▲0.021 | ▲0.021 |
| Debt Service Coverage Ratio | 0.000 | ▼-3.910 | ▼-2.344 |
| Interest Coverage Ratio | 0.000 | ▼-4.506 | ▼-19.619 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▼-0.859 |
| Operating Cash Flow Coverage Ratio | 1.885 | ▲0.576 | ▲0.689 |
| Capital Expenditure Coverage Ratio | 23.021 | ▲7.434 | ▲6.237 |
| Dividend Paid And Capex Coverage Ratio | 23.021 | ▲7.434 | ▲6.237 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 20.724 | ▼-1.047 | ▼-15.533 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $14.11B | $13.70B | $12.87B | $11.44B | $8.06B | |
| Enterprise value | $13.81B | $13.93B | $13.05B | $11.44B | $8.16B | |
| EV / Sales | 4.83x | 5.91x | 6.92x | 7.69x | 7.20x | |
| EV / Op. cash flow | 17.65x | 23.39x | 33.47x | 33.71x | 31.80x | |
| EV / Free cash flow | 18.45x | 24.99x | 36.09x | 35.44x | 34.99x | |
| EV / EBITDA | 20.72x | 21.77x | 31.36x | 48.36x | 59.06x | |
| Net debt / EBITDA | -0.45x | 0.35x | 0.43x | 0.00x | 0.72x | |
| Current ratio | 3.39x | 3.40x | 2.45x | 2.70x | 3.96x | |
| Income quality | 1.64x | 1.75x | 1.56x | 2.20x | 2.86x | |
| Graham number | $59 | $44 | $36 | $25 | $18 | |
| Graham net-net | $7 | $3 | $4 | $6 | $2 | |
| Tax burden | 67.8% | 70.2% | 75.2% | 72.2% | 88.4% | |
| Interest burden | 110.8% | 79.3% | 84.1% | 96.8% | 79.7% | |
| Working capital | $1.78B | $1.22B | $952.2M | $915.8M | $727.0M | |
| Invested capital | $2.32B | $1.85B | $1.33B | $1.10B | $882.8M | |
| Return on assets | 10.3% | 9.2% | 7.7% | 6.5% | 4.3% | |
| Operating ROA | 14.8% | 16.4% | 8.9% | 11.2% | 5.4% | |
| Return on tangible assets | 10.3% | 9.3% | 7.8% | 6.6% | 4.3% | |
| Return on equity | 14.7% | 13.2% | 11.2% | 9.0% | 6.5% | |
| Return on invested capital | 10.8% | 12.5% | 6.8% | 9.0% | 5.0% | |
| Return on capital employed | 15.9% | 17.8% | 9.7% | 13.6% | 5.6% | |
| Earnings yield | 3.4% | 2.5% | 1.9% | 1.4% | 1.1% | |
| Free cash flow yield | 5.3% | 4.1% | 2.8% | 2.8% | 2.9% | |
| Capex / Op. cash flow | 4.3% | 6.4% | 7.3% | 4.9% | 9.1% | |
| Capex / Depreciation | 113.0% | 141.0% | 132.9% | 105.8% | 214.7% | |
| Capex / Sales | 1.2% | 1.6% | 1.5% | 1.1% | 2.1% | |
| SG&A / Sales | 40.4% | 42.8% | 47.0% | 50.6% | 51.5% | |
| R&D / Sales | 35.5% | 31.0% | 29.9% | 31.2% | 28.9% | |
| Stock comp / Sales | 7.6% | 8.3% | 10.3% | 11.6% | 11.8% | |
| Intangibles / Total assets | 0.0% | 1.0% | 1.1% | 1.6% | 0.0% | |
| Days sales outstanding | 88d | 74d | 85d | 86d | 60d | |
| Days payables outstanding | 735d | 1072d | 1226d | 1059d | 1315d | |
| Operating cycle | 571d | 690d | 437d | 638d | 838d | |
| Cash conversion cycle | -164d | -382d | -788d | -421d | -476d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+3.0%EV / Sales ▼-18.3%EV / EBITDA ▼-4.8%EV / Op. cash flow ▼-5.741Earnings yield ▲+0.009Graham number ▲+15.067
Profitability
Return on equity ▲+0.015Return on assets ▲+0.012Return on invested capital ▼-0.017Return on capital employed ▼-0.018Operating ROA ▼-0.015Income quality ▼-0.109Tax burden ▼-0.024
Efficiency
Days sales outstanding ▲+13.390Days payables outstanding ▼-337.552Operating cycle ▼-119.419Cash conversion cycle ▲+218.133Capex / Sales ▼-0.004R&D / Sales ▲+0.045
Balance-sheet strength
Current ratio ▼-0.004Net debt / EBITDA ▼-0.794Working capital ▲+562300000.000Invested capital ▲+479000000.000Intangibles / Total assets ▼-0.010
Change over 5 years
Valuation
Market cap ▲+75.2%EV / Sales ▼-32.9%EV / EBITDA ▼-64.9%EV / Op. cash flow ▼-14.150Earnings yield ▲+0.023Graham number ▲+41.891
Profitability
Return on equity ▲+0.082Return on assets ▲+0.060Return on invested capital ▲+0.058Return on capital employed ▲+0.103Operating ROA ▲+0.094Income quality ▼-1.227Tax burden ▼-0.205
Efficiency
Days sales outstanding ▲+27.903Days payables outstanding ▼-579.606Operating cycle ▼-267.197Cash conversion cycle ▲+312.410Capex / Sales ▼-0.009R&D / Sales ▲+0.066
Balance-sheet strength
Current ratio ▼-0.564Net debt / EBITDA ▼-1.168Working capital ▲+1052300000.000Invested capital ▲+1441700000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-06-17 | Lisa McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-11 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2024-11-19 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2024-08-26 | Michael McCaul | Sale | $1,001 - $15,000 |
| 2023-10-27 | Michael McCaul | Sale | $50,001 - $100,000 |
| 2023-10-27 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-08-14 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2023-08-14 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2023-05-02 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-05-02 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-02-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-16 | Michael McCaul | Sale | $1,001 - $15,000 |
| 2022-12-16 | Michael McCaul | Sale | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-28 | Michael McCaul | Sale | $1,001 - $15,000 |
| 2022-01-28 | Michael McCaul | Sale | $1,001 - $15,000 |
| 2021-12-21 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2021-12-14 | Michael McCaul | Sale | $1,001 - $15,000 |
| 2021-03-09 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2021-03-09 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2020-12-21 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-11-12 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2020-07-21 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
Recent news
- 2026-07-31 NBIX Q2 Earnings Call Highlights: Portfolio Expansion Drives Growth Neurocrine expands its portfolio with INGREZZA, CRENESSITY and VYKAT XR growth, while advancing pipeline catalysts and commercial momentum.
- 2026-07-30 Neurocrine Biosciences, Inc. (NBIX) Q2 2026 Earnings Call Transcript Neurocrine Biosciences, Inc. (NBIX) Q2 2026 Earnings Call Transcript
- 2026-07-30 Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say The headline numbers for Neurocrine (NBIX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 2026-07-30 Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates Neurocrine Biosciences (NBIX) came out with quarterly earnings of $2.85 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $1.06 per share a year ago.
- 2026-07-30 Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA ® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 Billion Acquisition of Soleno Therapeutics Completed in May 2026 SAN DIEGO, July 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2026. "Our second quarter performance demonstrates the power of a strategy designed to compound over time," said Kyle W.
- 2026-07-29 Neurocrine (NBIX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates Looking beyond Wall Street''s top-and-bottom-line estimate forecasts for Neurocrine (NBIX), delve into some of its key metrics to gain a deeper insight into the company''s potential performance for the quarter ended June 2026.
- 2026-07-27 Neurocrine Gears Up to Report Q2 Earnings: What''s in the Cards? NBIX heads into Q2 results with a focus on Ingrezza sales, Crenessity growth and pipeline updates as investors watch key commercial and clinical progress.
- 2026-07-23 Neurocrine Biosciences Announces Key Leadership Hiring, Promotions SAN DIEGO, July 23, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of three Senior Vice Presidents, further strengthening its leadership team as the company executes its next phase of growth, expands its commercial portfolio and advances one of the industry''s strongest neuroscience pipelines. These appointments reflect Neurocrine''s continued evolution into a diversified, multi-product biopharmaceutical company positioned to deliver sustainable long-term growth.
- 2026-07-23 Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week''s Release Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 2026-07-22 California Public Employees Retirement System Purchases 25,620 Shares of Neurocrine Biosciences, Inc. $NBIX California Public Employees Retirement System raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 13.0% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 222,441 shares of the company''s stock after buying an additional 25,620 shares during the quarter. California